
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY

Intrinsic Value
The intrinsic value of one
ALNY
stock under the Base Case scenario is
184.46
USD.
Compared to the current market price of 262.16 USD,
Alnylam Pharmaceuticals Inc
is
Overvalued by 30%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Alnylam Pharmaceuticals Inc
Fundamental Analysis

Despite Alnylam’s leadership in RNAi therapies, the company’s path to consistent profitability is not guaranteed, given its reliance on a relatively small number of approved drugs and uncertainty around insurance coverage, which could constrain revenue growth.
Alnylam’s first-to-market advantage in RNAi therapeutics positions it to capture significant market share in rare disease segments. Strong demand for its commercialized products, such as ONPATTRO and GIVLAARI, could drive robust revenue growth.

Revenue & Expenses Breakdown
Alnylam Pharmaceuticals Inc
Balance Sheet Decomposition
Alnylam Pharmaceuticals Inc
Current Assets | 3.3B |
Cash & Short-Term Investments | 2.7B |
Receivables | 405.3m |
Other Current Assets | 195.5m |
Non-Current Assets | 944.7m |
PP&E | 693.9m |
Other Non-Current Assets | 250.8m |
Free Cash Flow Analysis
Alnylam Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Alnylam Pharmaceuticals Inc
Revenue
|
2.2B
USD
|
Cost of Revenue
|
-323.4m
USD
|
Gross Profit
|
1.9B
USD
|
Operating Expenses
|
-2.1B
USD
|
Operating Income
|
-176.9m
USD
|
Other Expenses
|
-101.3m
USD
|
Net Income
|
-278.2m
USD
|
ALNY Profitability Score
Profitability Due Diligence
Alnylam Pharmaceuticals Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

Score
Alnylam Pharmaceuticals Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
ALNY Solvency Score
Solvency Due Diligence
Alnylam Pharmaceuticals Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Score
Alnylam Pharmaceuticals Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALNY Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
ALNY
is 324.51 USD
with a low forecast of 196.95 USD and a high forecast of 525 USD.
Dividends
Current shareholder yield for ALNY is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ALNY
stock under the Base Case scenario is
184.46
USD.
Compared to the current market price of 262.16 USD,
Alnylam Pharmaceuticals Inc
is
Overvalued by 30%.